

## Exome sequencing identifies *ABCA7* as an important gene for familial AD cases from Eastern India

<sup>1\*</sup>Dipanwita Sadhukhan, <sup>2\*</sup>Adreesh Mukherjee, <sup>2</sup>Bidisha Bhattacharyya, <sup>1</sup>Smriti Mishra, <sup>1</sup>Tapas Kumar Banerjee, <sup>2</sup>Gautam Das, <sup>2</sup>Uma Sinharoy, <sup>3</sup>Subhra Prakash Hui, <sup>4</sup>Soma Gupta, <sup>2</sup>Atanu Biswas, <sup>1,4</sup>Arindam Biswas  
(\*Joint first author)

<sup>1</sup>Molecular Biology & Clinical Neuroscience Division, National Neurosciences Centre, Calcutta, Kolkata, India;

<sup>2</sup>Institute of Postgraduate of Medical Education & Research and Bangur Institute of Neurosciences, Kolkata, India;

<sup>3</sup>S. N. Pradhan Centre for Neurosciences, University of Calcutta, Kolkata, India

<sup>4</sup>DBT-NIDAN Kendra, Nilratan Sircar Medical College, Kolkata, India

Keywords: Whole Exome Sequencing, Alzheimer's Disease, Mutations, *ABCA7*, Indians

Short Title: Whole exome analysis in AD patients from eastern India

### \*Corresponding author:

Dr. Arindam Biswas  
Molecular Biology & Clinical Neuroscience Division  
National Neurosciences Centre, Calcutta  
Peerless Hospital (2<sup>nd</sup> floor)  
360, Panchasayar, Kolkata 700094  
West Bengal, India  
Email: [thisisarindam@gmail.com](mailto:thisisarindam@gmail.com)

Prof. Atanu Biswas  
Department of Neurology  
IPGME&R and Bangur Institute of Neurosciences  
52/1A, S.N. Pandit Street, Kolkata 700025  
West Bengal, India.  
E-mail: [atabis@gmail.com](mailto:atabis@gmail.com)

## ABSTRACT

### Introduction:

AD is the most complex disorder leading to dementia worldwide. Despite the disease burden among Indians the mutation spectrum in our subcontinent is not well examined.

### Methods:

To identify probable causal variants for AD, in a total of 29 clinically diagnosed, majorly familial and young onset AD cases from Eastern India, whole exome analysis in Illumina NovoSeq. 6000 sequencing platform was performed as per standard methodology. Next, the coding variants were prioritised based on the literature and our bioinformatic analyses for genotype-to-phenotype correlation.

### Results:

A total of 25 missense variants and 4 nonsense variants in 17 genes among 23 AD cases were identified as probable damaging ones in our study cohort. Amongst all, *ABCA7* account for the maximum number of pathogenic variants (5/29). A lowering in the age of onset was observed for mutation carriers and cases belonging to the posterior cortical atrophy (PCA) subgroup. Our further comparative analyses suggested that variants in APP metabolism pathway genes are more common in PCA, frontal AD, and young-onset multi-domain amnesic phenotypes than dysexecutive and typical AD.

### Conclusion

Our study suggests that whole exome sequencing among Indian AD patients holds the potential to identify the most common gene as well as clinically relevant new causal variants which may highlight new insight into disease mechanism through future research.

## **INTRODUCTION**

Alzheimer's disease (AD) is the most common progressive neurodegenerative disorder, with varying degrees of manifestation between individuals of the same ethnicity. Among Indians, the prevalence rate of dementia is 7.4% (around 8.8 million individuals) over the age of 60 years (Lee et al., 2023) of which AD alone or in combination with vascular pathology constitutes the majority. However, in contrast to European Ancestry, little is known about the Indian genetic architecture conferring AD susceptibility. The maximum number of reports are on the genetic association of AD with ApoE4 (Bharath et al., 2010, Shankarappa et al., 2017). However, an earlier Whole exome sequencing (WES) has been successful in the identification of pathogenic AD-associated novel variants among Indians (Syama et al., 2018). Therefore, considering complex disease mechanisms, little knowledge of AD genetics, and highly heritable polygenic AD susceptibility ( $h^2=0.58-0.79$ ) (Karlsson et al., 2022), the present study aimed to adopt a WES strategy to highlight the genes probably associated with Familial Alzheimer's Diseases (FAD) from eastern India.

## **MATERIALS AND METHODS**

### **Study subjects**

Based on radiological findings and standard diagnostic criteria for AD by National Institute on Aging and Alzheimer's Association (NIA-AA) Workgroup criteria (Jack et al., 2024) here a total of 29 AD subjects with either positive family history or younger age of onset were recruited by Cognitive Neurologists and Neuropsychologists from the Bangur Institute of Neurosciences and National Neurosciences Centre Calcutta, Kolkata, India. Among them, 22 had a younger age of onset (< 65 years), and 24 had a positive family history of AD or dementia.

### **Whole exome sequencing**

To perform WES, genomic DNA was extracted using the QIAamp DNA Blood kit (QIAGEN, Germany) followed by targeted gene capture using a custom capture kit. Paired-end sequencing was performed with 2x100/2x150 chemistry on Illumina NovoSeq 6000 sequencing platform. Reads were assembled and aligned to reference sequences based on NCBI RefSeq transcripts and human genome build GRCh37/UCSC hg19.

### ***In-silico* analyses**

The variation calling, annotation, and prioritization were performed to identify the variants of interest and interpreted in the context of a single clinically relevant transcript. All variants identified in known 36 genes for AD and other dementia-related genes/loci were manually evaluated based on documented literature, online database and bioinformatics prediction. The nonsynonymous variants that showed damaging effects by more than 60% of tools used (13/21) or more would be considered probable damaging and reported here.

## Results

### Demographic details of the study cohort:

To understand the genetic basis of AD in the Eastern Indian AD population, we performed a pilot WES in a total of 29 AD patients with cognitive impairment for an average of more than 1.5 years at the time of presentation. The mean age at onset is  $55.03 \pm 11.59$  years and age ranges from 35 to 74 years. The male-to-female ratio is 0.6111. An except for 5 cases, all of them have a positive family history.

### Identification of genetic variants

Among the plethora of variants identified, here we report a total of 25 missense variants and 4 nonsense variants with high pathogenicity in 17 genes among 23 AD cases representing ~79.31% (23/29) cases as carriers.

It includes majorly five missense mutations in *ABCA7* (distributed throughout the protein), three in *SORL1* (a novel and two reported), two novel variants like Phe383Val and Leu258Ser in *PSENI* (in TM6, TM7) and the pathogenic Val717Ile in *APP* gene. Apart from these, dementia and PD-related genes also appeared to carry pathogenic variants among AD patients (Table 1a). The Ser15ProfsTer39 of *EIF4G1*, Trp218Ter of *GBA*, Phe7LeufsTer80 of *UNC13B*, and Lys484Ter of *VPSI3C* variants account for the nonsense variant identified here.

In contrast, missense variants mentioned in Table 1b (Arg566Cys in *EIF4G1*, Pro455Leu & Ala2075Glu in *ABCA7* and Arg202Gln in *GBA* genes) showed less damaging effects upon analyses.

### Phenotypic variability and relation to genotype

To explain the genotype-to-phenotype relation, it is noteworthy to mention that sixteen patients had a monogenic mutation and 7 cases were digenic/double mutants for these genes.

Typical AD, Posterior Cortical Atrophy (PCA), and Frontal variant of AD appeared as common clinical features followed by young-onset multi-domain amnesic and dysexecutive syndrome (Table 1b) in our study cohort.

Our preliminary comparisons of the age of onset between the groups showed that it is a) lowest for PCA and highest for typical AD (P-value=0.0423 and 0.0001297 respectively) and b) lower among the mutation carriers than non-carriers ( $53\pm 11.21$  vs  $62.83\pm 10.40$ ; P=0.08438) (Table 2a).

Our further inter-group analysis showed that the genetic variants in the APP metabolism (for PCA 78%, for frontal variant 75%, for young-onset multi-domain amnesic 67%, and 36% for typical AD) and non-APP metabolism pathway (100% for the dysexecutive syndrome, 64% for typical AD, 33% for young-onset multi-domain amnesic, 25% for frontal variant, and 22% for PCA) are present across phenotypes in different frequencies (Table 2b). Therefore, the categorization of genes linked with AD according to metabolic pathway suggests that alterations in genes of the APP metabolism pathway are likely to result in PCA, frontal AD and young-onset multi-domain amnesic, while, non-APP metabolism pathway involvement may show dysexecutive, and typical AD.

The APOE4 load is quite high here; 18 individuals are found with the *APOE4* allele in heterozygous condition and two were homozygous for the same. The *E4* allele is present irrespective of the different AD variants.

## DISCUSSION

Therefore, in the present study, after screening 29 AD patients from Eastern India we have identified several probable pathogenic variants in a total of 17 genes majorly in *ABCA7*, *SORL1*, *APP* and *PSENI*.

The London variant in the *APP* gene that we identified here too, is known as the mutational hotspot for autosomal dominant AD. An increased  $A\beta_{1-42}/A\beta_{1-40}$  leading to more pathological protein accumulation is the underlying mechanism for it. On the other hand, *PSENI* variants located in its transmembrane domains, TM6 and TM7 respectively are novel and uncharacterised. However, since these variants share the same domains with the two major catalytic aspartic acids (Asp275 and Asp385) which are important for their endoproteolytic activity and  $\gamma$ -secretase activity, here we speculate for a deficiency in protein's function as their patho-mechanism towards early-onset AD. Amongst all the genes, *ABCA7* was identified to carry the maximum number of variants which are clustered in Extracellular loop1 and NBD motif followed by 2nd transmembrane helix. A variability in the age of onset

for *ABCA7* carriers was observed in our study. Several factors like the location of variants, *APOE* genotype, and the presence of additional variants in other AD or PD-related genes could be reasons for such variable clinical manifestations. Unlike a previous study examining *ABCA7* variants in AD cases with memory and non-memory cognitive impairment, here we found severe memory impairment in all carriers (Campbell et al., 2022). In line with growing evidence from candidate and GWAS studies, our study has also identified *SORLI* as an important gene conferring risk to AD in familial cases. Our intergroup analysis also highlighted the contribution of non-APP pathway genes across different AD varieties even in a very small sample size.

An earlier study from India on AD-exome analysis already identified variants in genes involved in APP metabolism like ours, but the profile is different concerning location in protein and frequency (Syama et al., 2018). However, considering these two studies, we can say APP-metabolism genes contribute significantly to familial AD among Indians. Moreover, our Indian data regarding the influence of *APOE* genotype on phenotypic heterogeneity is in accordance with global data.

Therefore, in conclusion, genes related to A $\beta$  formation and clearance can be termed as major players in Indian familial AD cases and future exome analyses in larger cohorts have the potential to identify new variants in common genes which can provide new disease insight through model study.

**Acknowledgement:** The authors thank the patients who participated in the study.

## References

- Bharath, S., Purushottam, M., Mukherjee, O., Bagepally, B. S., Prakash, O., Kota, L., Krishnappa, S. B., Sivakumar, P. T., Jain, S., & Varghese, M. (2010). Apolipoprotein E polymorphism and dementia: a hospital-based study from southern India. *Dementia and geriatric cognitive disorders*, *30*(6), 455–460. <https://doi.org/10.1159/000322093>
- Campbell, A. S., Ho, C. C. G., Atik, M., Allen, M., Lincoln, S., Malphrus, K., Nguyen, T., Oatman, S. R., Corda, M., Conway, O., Strickland, S., Petersen, R. C., Dickson, D. W., Graff-Radford, N. R., & Ertekin-Taner, N. (2022). Clinical Deep Phenotyping of *ABCA7* Mutation Carriers. *Neurology. Genetics*, *8*(2), e655. <https://doi.org/10.1212/NXG.0000000000000655>
- Jack, C. R., Jr, Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., Molinuevo, J. L., Okonkwo, O. C., Pani, L., Rafii, M. S., Scheltens, P., Siemers, E., Snyder, H. M., Sperling, R., Teunissen, C. E., & Carrillo, M. C. (2024). Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimer's & dementia: the journal of the Alzheimer's Association*, *10*.1002/alz.13859. Advance online publication. <https://doi.org/10.1002/alz.13859>
- Karlsson, I. K., Escott-Price, V., Gatz, M., Hardy, J., Pedersen, N. L., Shoai, M., & Reynolds, C. A. (2022). Measuring heritable contributions to Alzheimer's disease: polygenic risk score analysis with twins. *Brain communications*, *4*(1), fcab308. <https://doi.org/10.1093/braincomms/fcab308>
- Lee, J., Meijer, E., Langa, K. M., Ganguli, M., Varghese, M., Banerjee, J., Khobragade, P., Angrisani, M., Kurup, R., Chakrabarti, S. S., Gambhir, I. S., Koul, P. A., Goswami, D., Talukdar, A., Mohanty, R. R., Yadati, R. S., Padmaja, M., Sankhe, L., Rajguru, C., Gupta, M., ... Dey, A. B. (2023). Prevalence of dementia in India: National and state estimates from a nationwide study. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, *19*(7), 2898–2912. <https://doi.org/10.1002/alz.12928>
- Shankarappa, B. M., Kota, L. N., Purushottam, M., Nagpal, K., Mukherjee, O., Viswanath, B., Varghese, M., Bharath, S., & Jain, S. (2017). Effect of *CLU* and *PICALM* polymorphisms on AD risk: A study from south India. *Asian journal of psychiatry*, *27*, 7–11. <https://doi.org/10.1016/j.ajp.2016.12.017>
- Syama, A., Sen, S., Kota, L. N., Viswanath, B., Purushottam, M., Varghese, M., Jain, S., Panicker, M. M., & Mukherjee, O. (2018). Mutation burden profile in familial Alzheimer's disease cases from India. *Neurobiology of aging*, *64*, 158.e7–158.e13. <https://doi.org/10.1016/j.neurobiolaging.2017.12.002>

**Funding:** Supported by grants from the Department of Science & Technology, Govt. of India, under the Cognitive Science Research Initiative Programme (DST/CSRI-P/2017/22), and Department of Biotechnology, Ministry of Science & Technology, Govt. of India (BT/NIDAN/01/05/2018).

**Credit authorship contribution statement:**

DS and AB were responsible for the concept, study design, experimental work, data analysis and manuscript preparation.

AM, AB, GD, US, and TKB were responsible for the clinical diagnosis, concept, study design and manuscript preparation.

BB and SM were responsible for data acquisition and manuscript preparation.

SPH and SG were responsible for manuscript preparation.

All authors read the draft, provided their inputs and agreed on the final version of the manuscript.

**Conflict of Interest:** There is no conflict of interest.

**Ethics statement:** All procedures performed in studies involving human participants were in accordance with the ethical standards of the IPGME&R, Kolkata, and National Neurosciences Centre Calcutta, Kolkata, India. The Ethics Committees (Institutional Ethics Committee, IPGME&R, Kolkata and National Neurosciences Centre Calcutta, Kolkata) of the abovementioned Institutes approved the study protocol. Informed consent was taken as per guidelines of the Indian Council of Medical Research, National Ethical Guidelines for Biomedical and Health Research involving human participants, India.

**Informed consent:** Informed consent from all the participants was received before clinical data and sample collection.

**Data Availability Statement:** The data described in this study are available from the corresponding author upon reasonable request.

**Table 1a: Description of genetic variants with a higher pathogenicity prediction score by *in-silico* tools**

Gene Name	cDNA change	Amino acid change	Protein domain	dbSNP ID	MAF (gnomAD v4.0.0)	Functional Prediction: Damaging (Total)	Comments
<i>APP</i>	c.2149G>A	Val171Ile	Intracellular domain	rs63750264	0.000002401	17 (21)	Amyloid precursor protein
<i>PSEN1</i>	c.1156T>C	Phe386Val	TM7	Novel	Not available	20 (21)	Proteolytic subunit of gamma-secretase, role in processing in APP
	c.785T>C	Leu258Ser	TM6	Novel	Not available	20 (21)	
<i>ABCA7</i>	c.1547G>C	Arg516Pro	Extracellular loop 1	rs377020137	0.00008299	15 (21)	Transporter involved in cholesterol metabolism and clearance of A $\beta$
	c.2974A>G	Ile992Val	NBD motif	rs574186698	0.00002544	15 (21)	
	c.4590G>A	Met1530Ile	2 <sup>nd</sup> TM helix	rs747309721	0.000001593	13 (21)	
	c.4606G>A	Val1536Ile	Extracellular loop	rs371168746	6.843E-07	15 (21)	
	c.5548G>A	Glu1850Lys	NBD motif	rs530609497	6.911E-07	17 (21)	
<i>SORL1</i>	c.1A>G	Met1Val	VPS1 domain	Novel	Not available	15 (20)	Role in APP processing and lysosomal targeting of A $\beta$
	c.808G>A	Glu270Lys	VPS10 domain	rs117260992	0.01757	16 (20)	
	c.3643C>T	Arg1215Trp	LDLR class A domain	rs776459268	0.00001054	17 (21)	
<i>CCNF</i>	c.62G>A	Arg21Gln	F-box	rs200973445	0.000005576	16 (21)	Associated with FTD/ALS
	c.1217G>A	Arg406Gln	Cyclin N-terminal	rs146438273	0.00197	17 (21)	
<i>DNAJC13</i>	c.3191A>G	Asp1064Gly	N-terminal to J domain	Not available	0.000002478	18 (21)	Associated with PD
	c.3887A>G	Glu1296Gly	N-terminal to J domain	rs61748101	0.006254	18 (20)	
	c.4546C>T	Arg1516Cys	C-terminal to J domain	rs79734612	0.0008753	16 (20)	
	c.5018A>G	Tyr1673Cys	C-terminal to J domain	rs79953286	0.05256	15 (20)	
<i>EIF4G1</i>	c.42_43del	Ser15ProfsTer39	N-terminal domain	Novel	Not available	Not applicable	Associated with dementia
<i>GBA</i>	c.653G>A	Trp218Ter	Glyco-hydro_30 domain	rs867929413	0.000002738	Not applicable	Associated with dementia
<i>CD2AP</i>	c.62G>A	Arg21Gln	1 <sup>st</sup> SHC domain	rs559978848	0.0001289	13 (21)	Regulates A $\beta$ generation by neuron-specific polarization of A $\beta$ in dendritic early endosome
<i>EPHA4</i>	c.1150G>C	Val384Leu	Fibronectin type III domain	Not available	Not available	14 (21)	Regulates spine morphology and plasticity in the brain
<i>LRRK2</i>	c.5237C>A	Ala1746Asp	ROC-COR domain	Novel	Not available	18 (21)	Processing in APP
<i>NOS3</i>	c.466G>A	Glu156Lys		rs141456642	0.0003607	19 (21)	Associated with AD
<i>PLA2G6</i>	c.1123G>A	Glu375Lys	ANK7 domain	Not available	0.0000012	17 (21)	Associated with neurodegeneration
<i>SPAST</i>	c.1532A>C	Glu511Ala	AAA-ATPase domain	CD103676	0.000001593	15 (21)	Regulation of microtubule dynamics
<i>TREM2</i>	c.155G>C	Arg52Pro	Ig-V set domain	CM1413005	Not available	17 (21)	Immunoglobulin superfamily receptor binds lipids and A $\beta$
<i>UNC13B</i>	c.21del	Phe7LeufsTer80	C2A domain	rs372094156		Not applicable	Involved in synaptic vesicle

							exocytosis
<i>VPS13C</i>	c.1450A>T	Lys484Ter	VPS13-alpha	Novel	Not available	Not applicable	Associated with PD
	c.7445G>A	Arg2482His	Putative WD40 domain	rs115481870	0.009195	16 (20)	

Twenty-one online software were used including SIFT, PolyPhen2-HDIV, PolyPhen2-HVAR, MutationTaster, MutationAssessor, FATHMM, PROVEAN, VEST4, MetaSVM, MetaLR, M-CAP, CADD, DANN, fathmm-MKL, Eigen, GenoCanyon, fitCons, GERP++, phyloP, phastCons and SiPhy. Damaging (Total) is the ratio of online software that predicted the variant as damaging among the 21 online software. cDNA: complementary deoxyribonucleic acid; dbSNP: dbSNP137 (<https://www.ncbi.nlm.nih.gov/snp/>); MAF gnomAD: the minor allele frequency of variants in the genome aggregation database (gnomAD v4.0.0).

**Table 1b: Clinical features of AD cases harboring potential pathogenic/likely pathogenic variants**

Sl. No.	Lab ID	Age at onset (in ranges)	Family History	Gender	ApoE status	Disease duration (yrs.)	Gene 1	Amino acid change/Nucleotide variants	Gene 2	Amino acid change	Clinical presentation	Additional features
1.	DEM247	45-50	Positive	M	e3e4	1.5	<i>APP</i>	Val717Ile	<i>SOLRI</i>	Glu270Lys	Young-onset MDA	Parkinsonism
2.	DEM334	55-60	Positive	M	e3e3	2	<i>APP</i>	Val717Ile	-	-	Young-onset MDA	Nil
3.	DEM307	45-50	Negative	F	e3e4	1.5	<i>PSEN1</i>	Leu258Ser	-	-	PCA	Pyramidal sign
4.	DEM323	35-40	Positive	F	e3e3	2.5	<i>PSEN1</i>	Phe386Val	-	-	PCA	Nil
5.	DEM262	40-45	Negative	F	e3e3	2	<i>ABCA7</i>	Arg516Pro	-	-	Frontal AD	Parkinsonism
6.	DEM268	45-50	Positive	F	e2e3	2.5	<i>ABCA7</i>	Ile992Val	-	-	PCA	Nil
7.	DEM264	65-70	Positive	M	e3e4	3	<i>ABCA7</i>	Met1530Ile	<i>PLA2G6</i>	Glu375Lys	Typical AD	Nil
8.	DEM239	45-50	Positive	F	e3e4	2	<i>ABCA7</i>	Val1536Ile	-	-	Frontal AD	Parkinsonism
9.	DEM290	65-70	Positive	F	e3e4	3	<i>ABCA7</i>	Glu1850Lys	-	-	Typical AD	Mild Parkinsonism
10.	DEM226	70-75	Positive	F	e3e4	2.5	<i>SORL1</i>	Met1Val	-	-	Typical AD	Nil
11.	DEM284	50-55	Positive	M	e3e3	2.5	<i>SORL1</i>	Arg1215Trp	<i>DNAJC13</i>	Glu1296Gly	PCA	Nil
12.	DEM283	35-40	Negative	F	e3e4	2	<i>CCNF</i>	Arg21Gln	<i>LRRK2</i>	Ala1746Asp	PCA	Nil
13.	DEM233	40-45	Positive	M	e3e4	2	<i>CCNF</i>	Arg406Gln	<i>DNAJC13</i>	Asp1064Gly	Frontal AD	Nil
14.	DEM332	75-80	Positive	F	e3e4	2	<i>DNAJC13</i>	Arg1516Cys	-	-	Typical AD	Nil
15.	DEM244	45-50	Negative	F	e3e4	1	<i>DNAJC13</i>	Tyr1673Cys	-	-	Young-onset MDA	Nil
16.	DEM305	50-55	Positive	M	e3e4	2	<i>GBA</i>	Trp218Ter	-	-	Typical AD	Parkinsonism
17.	DEM291	65-7	Positive	M	e4e4	2	<i>EIF4G1</i>	Ser15ProfsTer39	-	-	Typical AD	Nil
18.	DEM235	60-65	Positive	F	e4e4	1.5	<i>EPHA4</i>	Val384Leu	-	-	Typical AD	Nil
19.	DEM328	55-60	Negative	F	e3e3	2	<i>CD2AP</i>	Arg21Gln	-	-	Typical AD	Nil
20.	DEM315	45-50	Positive	F	e3e3	1.5	<i>NOS3</i>	Glu156Lys	<i>SPAST</i>	Glu511Ala	PCA	Nil
21.	DEM329	60-65	Positive	F	e3e3	2	<i>TREM2</i>	Arg52Pro	-	-	Frontal AD	Nil
22.	DEM311	60-65	Positive	F	e3e4	1	<i>VPS13C</i>	Lys484Ter	<i>VPS13C</i>	Arg2482His	PCA	Nil
23.	DEM287	40-45	Positive	F	e3e4	3	<i>UNC13B</i>	Phe7LeufsTer80	-	-	Dysexecutive	Nil
24.	DEM227	65-70	Positive	F	e3e3	3	<i>EIF4G1</i>	Arg566Cys	-	-	Typical AD	Nil
25.	DEM229	60-65	Positive	F	e3e4	1.5	<i>ABCA7</i>	c.5848-5C>T	-	-	PCA	Nil
26.	DEM240	70-75	Positive	F	e3e4	1.5	<i>NOTCH3</i>	Leu33del	-	-	Typical AD	Nil
27.	DEM269	65-70	Positive	M	e3e4	3	<i>ABCA7</i>	Pro455Leu	-	-	Typical AD	Nil
28.	DEM295	40-45	Positive	M	e3e4	2	<i>ABCA7</i>	Ala2075Glu	-	-	PCA	Nil
29.	DEM335	60-65	Positive	M	e3e4	2	<i>GBA</i>	Arg202Gln	<i>NOTCH3</i>	Arg2145Gln	Dysexecutive	Nil

PCA: Posterior Cortical Atrophy; MDA: Multidomain Amnesic; AD: Alzheimer's Disease

**Table 2a: Comparison of Age at onset for different subgroups of AD**

Phenotypic variety	Mean Age at Onset $\pm$ SD	P-value
Typical AD (n = 11) vs others	65.45 $\pm$ 7.72 vs 48.67 $\pm$ 8.55	<b>0.0001297</b>
Posterior cortical atrophy (n = 9) vs others	48 $\pm$ 9.62 vs 58.2 $\pm$ 11.19	<b>0.0423</b>
Frontal AD (n = 4) vs others	48.25 $\pm$ 9.60 vs 56.12 $\pm$ 11.68	0.1834
Young-onset Multi-domain amnesic (n = 3) vs others	49.33 $\pm$ 5.50 vs 55.69 $\pm$ 11.99	0.4094
Dysexecutive syndrome (n = 2) vs others	51.5 $\pm$ 12.02 vs 55.29 $\pm$ 11.75	0.4904
Probable mutation carriers (n = 23) vs non-carriers (n = 6)	53 $\pm$ 11.21 vs 62.83 $\pm$ 10.40	0.08438

**Table 2b: Comparison between phenotypic variability with mean age at onset and APP metabolism pathway**

Phenotypic variety	Pathway involved	Mean Age at Onset $\pm$ SD	P-value
Typical AD (n = 11)	APP metabolism (4; 36%)	67.75 $\pm$ 2.87	0.6335
	Non-APP metabolism (7; 64%)	64.14 $\pm$ 9.47	
Posterior cortical atrophy (n = 9)	APP metabolism (7; 78%)	46.28 $\pm$ 9.30	0.5565
	Non-APP metabolism (2; 22%)	54 $\pm$ 11.31	
Young-onset Multi-domain amnesic (n = 3)	APP metabolism (2; 67%)	52 $\pm$ 4.24	0.6667
	Non-APP metabolism (1; 33%)	44	
Frontal variant (n = 4)	APP metabolism (3; 75%)	49.67 $\pm$ 11.23	1.00
	Non-APP metabolism (1; 25%)	44	
Dysexecutive syndrome (n = 2)	Non-APP metabolism (2; 100%)	51.5 $\pm$ 12.02	Not applicable